Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma

Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Şendur, Mehmet A. N., Aksoy, Sercan, Özdemir, Nuriye Yıldırım, Zengin, Nurullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912798/
https://www.ncbi.nlm.nih.gov/pubmed/24550600
http://dx.doi.org/10.4103/0253-7613.125195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912798/
https://www.ncbi.nlm.nih.gov/pubmed/24550600
http://dx.doi.org/10.4103/0253-7613.125195

Ejemplares similares